Table 2.

Intergroup comparison of key efficacy endpoints at 1 yr

ATG (n = 113)Daclizumab (n = 114)P value
BPAR17 (15.0%)31 (27.2%)0.016
    Borderline changes23
    Grade I85
    Grade IIa313
    Grade IIb15
    Grade III24
    Pure AMR11
Steroid-resistant rejection3 (2.7%)17 (14.9%)0.002
Median time to rejection (d) [interquartile range 25 to 75%]35 [13 to 164]13 [9 to 19]0.007
Recurrent rejection4 (3.6%)7 (6.1%)0.54
Delayed graft function35 (31.5%)50 (44.6%)0.044
Graft loss20 (17.7%)16 (14.0%)0.47
    From death with functioning graft3 (2.7%)4 (3.5%)
    From primary nonfunction3 (2.7%)2 (1.8%)
    From vascular thrombosis2 (1.8%)1 (0.9%)
    From uncontrolled rejection3 (2.7%)3 (2.6%)
    From hemolytic uremic syndrome2 (1.8%)1 (0.9%)
    From technical failure2 (1.8%)1 (0.9%)
    From BK virus2 (1.8%)0
    From other causes3 (2.7%)4 (3.5%)
Death5 (4.4%)4 (3.5%)0.75
    From stroke2 (1.8%)0
    From sepsis2 (1.8%)1 (0.9%)
    From bleeding01 (0.9%)
    From cancer1 (0.9%)0
    From cardiac arrest01 (0.9%)
    Unknown cause01 (0.9%)